Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging
Alzheimer's & Dementia · 2026-04 · 22 (4)
DOI: 10.1002/alz.71227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.04.2026. Verfasst von Mingzhao Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Aging, Cognition. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, GHR Foundation, National Institute on Aging.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION We examined when Alzheimer's disease biomarkers become informative by identifying age‐related breakpoints with slope‐changing trajectories. METHODS In 2082 Mayo Clinic Study of Aging participants, we modeled plasma amyloid beta (Aβ)42/40, phosphorylated tau (p‐tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), amyloid/tau positron emission tomography (PET), hippocampal volume (HVa), and global cognition. Generalized additive models described age trends; Davies' test and piecewise linear regression estimated breakpoints. A C2N subsample ( n = 462) provided mass‐spectrometry plasma markers (p‐tau181, p‐tau217, their ratios, Aβ42/40). RESULTS In the full cohort, Aβ42/40, HVa, and cognition declined with age; p‐tau181, NfL, GFAP, and amyloid/tau PET increased. We observed single breakpoints (years, 95% CI): GFAP 68.1 (63.5–71.8), NfL 70.7 (65.9–75.6), p‐tau181 67.2 (60.3–70.3), amyloid PET 62.3 (56.2–69.3), HVa 68.1 (63.1–71.9), cognition 59.8 (55.4–66.0); tau PET showed none. In the mass‐spectrometry subset, p‐tau217 and p‐tau181 broke at 72.6; their ratios and Aβ42/40 showed no breakpoints. DISCUSSION Breakpoints cluster near late midlife, suggesting windows for screening and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
ORCID-Profile: Jonathan Graff-Radford
Förderung
- NIA NIH HHS
- GHR Foundation
- National Institute on Aging
Zitieren
APA
Hu, M., Knopman, D. S., Therneau, T., Fought, A. J., Hofrenning, E., Lowe, V. J., Petersen, R. C., Algeciras-Schimnich, A., Jack, C. R., Stricker, N. H., Mielke, M. M., Vemuri, P., & Graff-Radford, J. (2026). Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging. Alzheimer's & Dementia, 22(4). https://doi.org/10.1002/alz.71227
Vancouver
Hu M, Knopman DS, Therneau T, Fought AJ, Hofrenning E, Lowe VJ, et al. Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging. Alzheimer's & Dementia. 2026;22(4). doi:10.1002/alz.71227
BibTeX
@article{Hu2026,
author = {Hu, Mingzhao and Knopman, David S and Therneau, Terry and Fought, Angela J and Hofrenning, Ekaterina and Lowe, Val J and Petersen, Ronald C and Algeciras-Schimnich, Alicia and Jack, Clifford R and Stricker, Nikki H and Mielke, Michelle M and Vemuri, Prashanthi and Graff-Radford, Jonathan},
title = {Breakpoints in Alzheimer's disease biomarkers and cognition across the aging spectrum: The Mayo Clinic Study of Aging},
journal = {Alzheimer's & Dementia},
year = {2026},
volume = {22},
number = {4},
doi = {10.1002/alz.71227}
}
EUVIMED